Beijing Biostar Pharmaceuticals Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Utidelone Capsule (Part 1) NCT05700084 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 84 | 2025-10-08 (+24 mo) |
| Utidelone combined with Bevacizumab NCT06683703 |
P2 | Not yet recruiting | Non-small Cell Lung Cancer Patients with Brain Metastases | 118 | 2026-12-01 |
| Utidelone Capsule 60mg/m2/d NCT06730581 |
P2 | Not yet recruiting | Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer | 100 | 2026-12-31 |
| Utidelone capsule 75mg/m2/d QD NCT07044349 |
P2 | Not yet recruiting | Ovarian Cancer; Fallopian Tube Cancer | 72 | 2027-03 |
| Utidelone Capsule NCT07684456 |
P3 | Not yet recruiting | Advanced Breast Cancer | 308 | 2028-03-01 |
| UTD2 + tislelizumab + doxorubicin NCT07842276 |
P2 | Not yet recruiting | Soft Tissue Sarcoma (STS); Utidelone | 49 | 2028-09-20 |
| Utidelone Capsule NCT06841679 |
P2/3 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma | 778 | 2030-09-01 |